We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| BeiGene Ltd | NASDAQ:BGNE | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 144.35 | 144.00 | 163.50 | 0 | 11:37:38 |
From Jul 2023 to Jul 2024
By Colin Kellaher
BeiGene on Wednesday said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of Brukinsa for certain patients with follicular lymphoma, the most common slow-growing non-Hodgkin lymphoma.
The Beijing biotechnology company said the application covers Brukinsa in combination with obinutuzumab for adults with relapsed or refractor follicular lymphoma after at least two prior lines of therapy.
BeiGene said the FDA has assigned a target action date in the first quarter of 2024, adding that approval would mark the fifth U.S. indication for Brukinsa.
BeiGene reported global Brukinsa sales of $211.4 million for the first quarter of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 12, 2023 07:33 ET (11:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year BeiGene Chart |
1 Month BeiGene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
